
`
`
`
`Global Research
`
`6 April 2018
`
`
`
`
`
`
`
`
`
`U.S. Pharmaceuticals
`UBS Large Cap Pharmaceuticals Handbook
`
`
`
`What’s new? Refreshed Handbook
`This publication consists of monthly therapeutic market models, TRx
`growth trends, market share & sales estimates, and monthly promotion
`detail tables for key products within large cap pharmaceuticals. For the first
`time, we have also included our Immuno-oncology market models (Figure 3
`- Figure 31).
`
`Diabetes market shares remain steady
`Market share for the DPP-IV class has declined marginally since our last
`update in September 2017 from 11.5% to 11.3%. Over the same period
`the SGLT-2 class has remained at 6.1%, while the GLP-1 class' share has
`increased from 5.7% to 6.2%.
`
`Eliquis continues to take share from Warfarin
`Eliquis has continued to gain share, increasing from 24.2% at the end of
`September 2017 to 27.8% at the end of February 2018. Xarelto's share
`remains below Eliquis', and has grown marginally during the same period
`(21.5% in September to 21.6% in February) while Warfarin has continued
`to lose share, dropping from 50.4% of the market down to 47.2% at the
`end of February (vs ~70% in early 2015).
`
`
`
`
`
`Figure 1: DPP-IV and SGLT-2 Share in the Diabetes Market
`
`18.5%
`
`17.5%
`
`16.5%
`
`15.5%
`
`14.5%
`
`13.5%
`
`12.5%
`
`11.5%
`
`SGLT-2
`
`DPP-IV
`
`•
`
`10.5%
`,1y 1h 16
`1h 1h
`,4
`A
`'54
`Cs
`cy,
`4 4,
`\
`
`,4
`,r;
`
`„
`
`N
`
`4'
`÷ o
`
`Cc
`
`o'
`tea. NJ 5¢,,
`
`
`
`Figure 2: Novel Anticoagulant Market Share
`
`Warfarin
`
`Pradaxa
`
`Xarelto
`
`Eliquis
`
`70.0%
`
`60.0%
`
`50.0%
`
`40.0%
`
`30.0%
`
`20.0%
`
`10.0%
`
`0.0%
`
`4,4N
`
`.1,
`44
`
`.1,
`
`.1.
`,•§' 4,4 40
`
`.1°
`.19
`I 4,4 4,4,
`45'
`
`p
`
`.1,,
`.1\
`49 454 19
`
`
`
`
`
`Equities
`
`Americas
`Pharmaceuticals
`
`
`
`
`
`Marc Goodman
`Analyst
`marc.goodman@ubs.com
`+1-212-713 1342
`Uy Ear
`Associate Analyst
`uy.ear@ubs.com
`+1-212-713 9312
`Zidong Zhang
`Associate Analyst
`zidong.zhang@ubs.com
`+1-212-713 2603
`
`www.ubs.com/investmentresearch
`
`Source: IMS Health
`
`
`
`
`This report has been prepared by UBS Securities LLC. ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON PAGE 93. UBS does and seeks to do business with companies
`covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report
`as only a single factor in making their investment decision.
`
`Mylan Ex.1089
`Mylan v. Sanofi - IPR2018-01676
`
`

`

`
`
`Figure 44: Endocrinology – Diabetes (Non-Insulin) Annual
`
`% of Total TRxs
`2020E
`2019E
`2018E
`2017
`2015
`2014
`2013
`2012
`2011
`2016
`128,939 138,576 143,396 149,412 157,649 166,935 169,525 175,280 182,291 187,760
`-0.4%
`7.5%
`3.5%
`4.2%
`5.5%
`5.9%
`1.6%
`3.4%
`4.0%
`3.0%
`26.5% 26.9% 26.0% 24.7% 22.9% 21.4% 20.4% 20.3% 19.6% 18.7%
`1.1%
`1.0%
`0.9%
`0.8%
`0.7%
`0.7%
`0.6%
`0.6%
`0.6%
`0.6%
`45.8% 48.9% 51.0% 51.5% 51.0% 51.3% 51.3% 51.0% 51.4% 51.7%
`9.0%
`5.0%
`4.0%
`3.6%
`3.4%
`3.4%
`3.4%
`3.5%
`3.5%
`3.5%
`0.3%
`0.3%
`0.3%
`0.3%
`0.3%
`0.2%
`0.2%
`0.2%
`0.2%
`0.2%
`
`2011
`
`2012
`
`2013
`
`Total Sales ($ Millions)
`2014
`2015
`2016
`
`2017
`
`2018E
`
`2019E
`
`2020E
`
`$227.6
`$223.7
`$230.1
`$216.7
`$438.6
`$323.6
`$2,823.0 $1,525.5
`$20.0
`$20.9
`
`$198.4
`$212.2
`$513.6
`$141.4
`$17.4
`
`$155.6
`$189.7
`$167.8
`$32.3
`$41.2
`$74.4
`$595.6 $1,106.9 $1,188.6
`$36.7
`$28.9
`$24.7
`$14.5
`$12.3
`$9.0
`
`$127.0
`$28.8
`$704.5
`$21.2
`$6.7
`
`$124.1
`$24.6
`$688.8
`$20.0
`$6.3
`
`$118.5
`$23.0
`$685.3
`$19.8
`$6.7
`
`$110.9
`$21.5
`$675.3
`$19.5
`$6.9
`
`1.2%
`0.0%
`1.1%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`2.3%
`0.0%
`
`6.1%
`1.1%
`0.1%
`7.3%
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`
`0.9%
`0.2%
`1.5%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`2.6%
`0.0%
`
`6.4%
`1.4%
`0.4%
`8.2%
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`
`0.6%
`0.4%
`1.8%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`2.9%
`0.0%
`
`6.2%
`1.3%
`0.9%
`8.3%
`
`0.0%
`0.3%
`0.0%
`0.0%
`0.0%
`0.0%
`0.3%
`
`0.4%
`0.6%
`2.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`3.0%
`0.0%
`
`6.1%
`1.2%
`1.1%
`8.3%
`
`0.5%
`1.4%
`0.0%
`0.0%
`0.0%
`0.0%
`1.9%
`
`0.3%
`0.7%
`2.2%
`0.2%
`0.0%
`0.2%
`0.0%
`0.0%
`3.6%
`0.0%
`
`5.9%
`0.9%
`1.4%
`8.4%
`
`1.0%
`2.7%
`0.4%
`0.0%
`0.0%
`0.0%
`4.1%
`
`0.2%
`0.7%
`2.3%
`0.4%
`0.0%
`0.9%
`0.0%
`0.0%
`4.4%
`0.0%
`
`5.8%
`0.7%
`1.8%
`8.4%
`
`1.2%
`2.7%
`0.8%
`0.0%
`0.0%
`0.0%
`4.7%
`
`0.2%
`0.7%
`2.4%
`0.2%
`0.0%
`1.9%
`0.0%
`0.0%
`5.4%
`0.1%
`
`5.9%
`0.5%
`1.9%
`8.3%
`
`1.3%
`2.4%
`1.5%
`0.0%
`0.0%
`0.0%
`5.2%
`
`0.1%
`0.6%
`2.5%
`0.1%
`0.0%
`2.5%
`0.1%
`0.0%
`6.0%
`0.2%
`
`5.8%
`0.4%
`1.9%
`8.1%
`
`1.5%
`1.8%
`2.0%
`0.0%
`0.0%
`0.0%
`5.4%
`
`0.0%
`0.5%
`2.4%
`0.0%
`0.0%
`2.8%
`0.6%
`0.0%
`6.4%
`0.2%
`
`5.6%
`0.4%
`1.8%
`7.8%
`
`1.6%
`1.6%
`2.3%
`0.3%
`0.0%
`0.0%
`5.9%
`
`0.0%
`0.4%
`2.5%
`0.0%
`0.0%
`2.7%
`0.9%
`0.2%
`6.8%
`0.2%
`
`5.4%
`0.3%
`1.8%
`7.5%
`
`$0.3
`$0.3
`$35.7
`$114.0
`$164.0
`$209.0
`$199.0
`$304.0
`$432.8
`$517.7
`$263.2
`$353.0
`$429.5
`$458.0
`$463.0
`$482.0
`$374.0
`$263.0
`$130.0
`$0.0
`$514.5 $1,343.3 $1,463.6 $1,947.3 $2,101.9 $2,055.2 $2,239.7 $2,376.7 $2,672.8
`$368.4
`$0.0
`$0.0
`$7.3
`$89.5
`$150.0
`$108.0
`$30.4
`$8.0
`-$9.3
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$1.3
`$1.6
`$1.2
`$0.0
`$0.0
`$0.0
`$10.2
`$207.8
`$698.6 $1,609.9 $2,235.6 $2,559.6 $2,643.9
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$118.6
`$540.8
`$930.6
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$151.0
`$0.0
`$886.1 $1,077.3 $1,910.3 $2,054.1 $2,935.6 $3,577.5 $4,345.1 $5,094.9 $5,846.4 $6,659.4
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$38.3
`$106.2
`$132.7
`$144.0
`
`$1,825.0 $2,136.0 $2,069.0 $2,123.0 $2,263.0 $2,286.0 $2,154.0 $2,248.1 $2,182.0 $2,103.9
`$278.2
`$351.0
`$396.0
`$291.6
`$242.1
`$237.4
`$219.6
`$192.3
`$184.1
`$173.9
`$25.7
`$107.1
`$227.7
`$260.4
`$564.8
`$775.0 $1,044.9
`$994.2 $1,008.1 $1,001.9
`$2,128.9 $2,594.1 $2,697.3 $2,686.1 $3,090.1 $3,319.5 $3,430.8 $3,438.9 $3,378.6 $3,284.2
`
` a Ir
`
`1.8%
`1.4%
`2.5%
`0.6%
`0.1%
`0.0%
`6.4%
`
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`
`$0.0
`$133.9
`$0.0
`$0.0
`$0.0
`$0.0
`$133.9
`
`$686.5
`$627.1
`$577.3
`$489.0
`$457.0
`$261.0
`$223.7
`$374.2
`$460.0
`$590.4
`$838.7
`$563.3 $1,148.8 $1,138.2
`$998.8 $1,252.7 $1,458.6 $1,673.2
`$19.9
`$167.7
`$405.8
`$0.0
`$17.3
`$126.3
`$219.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$9.6
`$25.6
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$806.9 $1,577.5 $2,001.0 $2,326.5 $2,437.6 $2,681.5 $2,978.4
`
`$66.6
`$36.2
`$42.5
`$445.0
`$64.2
`$0.0
`$654.5
`$54.1
`
`$59.7
`$40.0
`$60.2
`$524.8
`$73.4
`$0.0
`$758.0
`$80.3
`
`Total Category Trx ('000)
` Growth Rate
`Total Sulfonylureas
`Total Glinides
`Total Biguanides
`Total Glitazone
`Total Alpha-Glucos Inhibitors
`Human GLP-1 Analogs
`Byetta - Astra Zeneca
`Bydureon - AstraZeneca
`Victoza - Novo Nordisk
`Tanzeum - GSK
`Adlyxin - Sanofi Aventis
`Trulicity (Dulaglutide) - Lilly
`Ozempic (Semaglutide) - Novo Nordisk
`Oral Semaglutide - Novo Nordisk
`Total GLP-1 Analog
`Total GLP-1/Insulin Combo
`DPP-4 Inhibitor,alone
`Januvia - Merck
`Onglyza - Astra Zeneca
`Tradjenta - LLY/BI
`Total DPP-4 Inhibitor, alone
`SGLT-2 Inhibitor
`Farxiga - Astra Zeneca
`Invokana - J&J
`Jardiance - Lilly/BI
`Steglatro (Steglatro) - Merck/Pfizer
`Sotagliflozin -Sanofi/Lexicon
`Remogliflozin - BHV Pharma
`Total SGLT-2 Inhibitor
`SGLT-2INHIB/Biguanide combo
`Invokamet - J&J
`Invokamet XR - J&J
`Ertugliflozin/metformin - Merck/Pfizer
`Xigduo XR - AstraZeneca
`Synjardy - Lilly/BI
`Synjardy XR - Lilly/BI
`Total SGLT-2INHIB/Biguanide combo
`Glitazone comb
`DPP-4INHIB/Biguanide comb
`Jentadueto - Lilly/BI
`Janumet/XR - Merck
`Kazano - Takeda
`Oseni - Takeda
`Kombiglyze XR - AstraZeneca
`Total DPP-4INHIB/Biguanide comb
`SGLT-2/DPP-IV Combo
`Qtern (Dapagliflozin/Onglyza) - AZN
`Ertugliflozin/Januvia combo - MRK/PFE
`Glyxambi - Lilly/BI
`Total SGLT-2/DPP-IV Combo
`Total Glinide/Biguanide
`Total Biguanide/Sulfonylurea Combos
`Dopamine Receptor
`Cycloset - Santarus
`Total Human Amylin analogs
`Total
` Growth Rate
`Source: Company reports, IMS database and UBS estimates
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`1.7%
`
`0.0%
`2.5%
`0.0%
`0.0%
`0.3%
`2.8%
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`3.1%
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.9%
`
`0.0%
`2.7%
`0.0%
`0.0%
`0.6%
`3.4%
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`2.6%
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.7%
`
`0.1%
`2.6%
`0.0%
`0.0%
`0.7%
`3.5%
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`2.2%
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.5%
`
`0.2%
`2.6%
`0.0%
`0.0%
`0.6%
`3.5%
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`1.7%
`
`0.2%
`0.0%
`0.0%
`0.2%
`0.0%
`0.0%
`0.4%
`0.4%
`
`0.2%
`2.5%
`0.0%
`0.1%
`0.5%
`3.4%
`
`0.0%
`0.0%
`0.1%
`0.1%
`0.0%
`1.3%
`
`0.3%
`0.0%
`0.0%
`0.3%
`0.0%
`0.0%
`0.6%
`0.3%
`
`0.3%
`2.5%
`0.0%
`0.0%
`0.4%
`3.2%
`
`0.0%
`0.0%
`0.2%
`0.2%
`0.0%
`1.1%
`
`0.3%
`0.1%
`0.0%
`0.3%
`0.1%
`0.0%
`0.8%
`0.2%
`
`0.3%
`2.4%
`0.0%
`0.0%
`0.3%
`3.0%
`
`0.0%
`0.0%
`0.2%
`0.2%
`0.0%
`0.9%
`
`0.2%
`0.1%
`0.0%
`0.4%
`0.1%
`0.0%
`0.9%
`0.2%
`
`0.2%
`2.3%
`0.0%
`0.0%
`0.2%
`2.8%
`
`0.0%
`0.0%
`0.2%
`0.2%
`0.0%
`0.7%
`
`0.2%
`0.1%
`0.1%
`0.4%
`0.1%
`0.0%
`1.0%
`0.2%
`
`0.2%
`2.2%
`0.0%
`0.0%
`0.2%
`2.6%
`
`0.1%
`0.1%
`0.2%
`0.3%
`0.0%
`0.4%
`
`0.2%
`0.2%
`0.2%
`0.4%
`0.1%
`0.0%
`1.1%
`0.2%
`
`0.2%
`2.1%
`0.0%
`0.0%
`0.2%
`2.5%
`
`0.0%
`0.1%
`0.2%
`0.4%
`0.0%
`0.1%
`
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$474.4
`
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$306.8
`
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$0.0
`$117.2
`
`$5.7
`$0.0
`$0.0
`$1.2
`$0.0
`$0.0
`$6.9
`$83.8
`
`$89.2
`$0.0
`$0.0
`$60.5
`$1.7
`$0.0
`$151.4
`$65.0
`
`$134.8
`$1.6
`$0.0
`$168.5
`$20.1
`$0.0
`$325.0
`$54.5
`
`$105.3
`$25.1
`$0.0
`$232.0
`$53.5
`$0.0
`$415.9
`$31.9
`
`$74.1
`$32.0
`$16.5
`$369.3
`$55.7
`$0.0
`$547.6
`$33.2
`
`$118.9
`$116.1
`$112.4
`$118.5
`$120.4
`$72.4
`$46.5
`$35.4
`$17.2
`$0.0
`$802.8
`$845.9
`$890.5
`$863.0
`$984.0
`$976.0
`$933.5
`$916.0
`$872.0
`$712.0
`$11.4
`$7.9
`$4.4
`$7.6
`$16.3
`$16.0
`$9.5
`$17.3
`$0.0
`$0.0
`$6.4
`$6.4
`$6.3
`$11.6
`$28.1
`$30.2
`$16.9
`$3.6
`$0.0
`$0.0
`$71.1
`$72.6
`$85.8
`$100.4
`$138.6
`$177.9
`$189.4
`$195.0
`$157.0
`$67.0
`$779.0 $1,046.2 $1,167.3 $1,195.8 $1,272.6 $1,287.5 $1,101.1 $1,099.5 $1,048.9 $1,010.7
`
`$0.0
`$0.0
`$0.0
`$0.0
`$2.2
`$52.2
`
`$0.0
`$0.0
`$0.0
`$0.0
`$1.9
`$38.0
`
`$0.0
`$0.0
`$0.0
`$0.0
`$1.9
`$35.8
`
`$0.0
`$0.0
`$0.0
`$0.0
`$1.8
`$30.5
`
`$0.0
`$0.0
`$62.1
`$62.1
`$1.7
`$32.6
`
`$0.0
`$0.0
`$166.8
`$166.8
`$0.7
`$33.8
`
`$0.0
`$0.0
`$151.0
`$151.0
`$0.1
`$9.0
`
`$8.4
`$21.1
`$153.8
`$183.3
`$0.0
`$7.1
`
`$25.7
`$78.8
`$168.4
`$272.9
`$0.0
`$4.2
`
`$27.8
`$125.6
`$177.7
`$331.1
`$0.0
`$1.7
`
`$0.0
`$0.0
`$9.7
`$9.2
`$11.6
`$14.6
`$28.4
`$16.6
`$14.4
`$12.2
`$27.7
`$25.2
`$22.6
`$24.8
`$29.8
`$37.2
`$51.5
`$68.9
`$91.6
`$103.9
`$8,045.9 $7,613.0 $7,232.1 $7,834.7 $10,619.4 $12,217.9 $12,771.9 $13,844.4 $14,952.4 $16,109.6
`14.3%
`-5.4%
`-5.0%
`8.3%
`35.5%
`15.1%
`4.5%
`8.4%
`8.0%
`7.7%
`
`
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.1%
`0.1%
`0.1%
`100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
`
` U.S. Pharmaceuticals 6 April 2018
`
`
`
` 46
`
`Mylan Ex.1089
`Mylan v. Sanofi - IPR2018-01676
`
`

`

`
`
`Figure 45: Endocrinology – Diabetes (Non-Insulin) Monthly
`
`Diabetes (Non-Insulin) TRx
`Total Category Rx
`Growth rate
`
`2019E
`2018E
`Dec-18E
`Nov-18E
`Oct-18E
`Sep-18E
`Aug-18E
`Jul-18E
`Jun-18E
`Apr-18E May-18E
`Feb-18 Mar-18E
`Jan-18
`2017
`169,525,312 14,506,052 13,089,349 15,442,495 14,355,777 15,367,305 14,994,323 14,659,527 15,073,602 14,185,979 14,897,298 14,270,154 14,421,272 175,263,133 182,273,658
`1.6% 0.9%
`-0.5%
`4.0%
`4.0%
`4.0%
`4.0%
`4.0%
`4.0%
`4.0%
`4.0%
`4.0%
`4.0%
`3.4%
`4.0%
`
`2017
`
`Jan-18
`
`Feb-18 Mar-18E
`
`Apr-18E May-18E
`
`Jun-18E
`
`Jul-18E
`
`Aug-18E
`
`Sep-18E
`
`Oct-18E
`
`Nov-18E
`
`Dec-18E
`
`2018E
`
`2019E
`
`20.4%
`
`20.2%
`
`20.1%
`
`20.3%
`
`20.3%
`
`20.2%
`
`20.3%
`
`20.2%
`
`20.2%
`
`20.3%
`
`20.3%
`
`20.3%
`
`20.2%
`
`20.2%
`
`19.5%
`
`0.0%
`0.4%
`0.0%
`0.2%
`50.8%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`50.9%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.0%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.0%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.0%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.0%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.1%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.1%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.1%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.2%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.2%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.2%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.3%
`
`0.0%
`0.0%
`3.4%
`0.2%
`
`0.2%
`0.0%
`0.7%
`2.4%
`1.9%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.1%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.1%
`0.1%
`0.6%
`2.5%
`2.6%
`0.1%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.4%
`0.0%
`0.2%
`51.4%
`
`0.0%
`0.0%
`3.5%
`0.2%
`
`0.0%
`0.1%
`0.5%
`2.4%
`2.8%
`0.6%
`0.0%
`0.0%
`0.6%
`
`Market Share
`Sulfonylureas
`Total Sulfonylureas
`Glinides,alone
`Prandin - Novo Nordisk
`Generic Prandin
`Starlix - Novartis
`Generic Starlix (Nateglinide)
`Biguanides, alone (Metformin)
`Glitazone,alone
`Actos - Takeda
`Avandia - GlaxoSmithkline
`Total Glitazone, alone
`Alpha-Glucos Inhibitor, alone
`Human GLP-1 Analogs
`Byetta - AstraZeneca
`Generic Byetta - Teva
`Bydureon - AstraZeneca
`Victoza - Novo Nordisk
`Trulicity (Dulaglutide) - Lilly
`Ozempic (Semaglutide) - Novo Nordisk
`Oral Semaglutide - Novo Nordisk
`Efpeglenatide - Sanofi/Hamni
`Other human GLP-1 analogs
`DPP-4 Inhibitor,alone
`Januvia - Merck
`Onglyza - AstraZeneca
`Tradjenta - LLY/BI
`Total DPP-4 Inhibitor
`Total SGLT-2 Inhibitor,alone
`Total SGLT-2INHIB/Biguanide combo
`Total Glitazone comb
`DPP-4INHIB/Biguanide combo
`Jentadueto - BI
`Janumet - Merck
`Janumet XR - Merck
`Juvisync - Merck
`Kazano - Takeda
`Oseni - Takeda
`Kombiglyze XR - AstraZeneca
`SGLT-2/DPP-IV Combo
`Qtern (Dapagliflozin/Onglyza) -
`Steglujan (Steglatro/Januvia combo) -
`Glyxambi - Lilly/BI
`Glinide/Biguanide combo
`Prandimet - Novo Nordisk
`Generic Prandimet
`Biguanide/sulfonylurea combo
`Total Human Amylin analogs
`Total
`
`0.1%
`0.0%
`0.7%
`2.6%
`2.4%
`0.0%
`0.0%
`0.0%
`0.1%
`
`6.0%
`0.5%
`1.9%
`8.4%
`5.3%
`0.8%
`0.2%
`
`0.2%
`1.6%
`0.9%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.1%
`0.0%
`0.6%
`2.7%
`2.5%
`0.0%
`0.0%
`0.0%
`0.1%
`
`5.9%
`0.4%
`1.9%
`8.3%
`5.3%
`0.8%
`0.2%
`
`0.2%
`1.6%
`0.9%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.1%
`0.0%
`0.6%
`2.6%
`2.4%
`0.0%
`0.0%
`0.0%
`0.1%
`
`5.9%
`0.4%
`1.9%
`8.2%
`5.4%
`0.8%
`0.2%
`
`0.2%
`1.5%
`0.9%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.1%
`0.0%
`0.6%
`2.5%
`2.5%
`0.0%
`0.0%
`0.0%
`0.1%
`
`5.9%
`0.4%
`1.9%
`8.2%
`5.4%
`0.8%
`0.2%
`
`0.2%
`1.5%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.1%
`0.1%
`0.6%
`2.5%
`2.5%
`0.1%
`0.0%
`0.0%
`0.1%
`
`5.8%
`0.4%
`1.9%
`8.2%
`5.4%
`0.8%
`0.2%
`
`0.2%
`1.5%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.1%
`0.1%
`0.6%
`2.5%
`2.6%
`0.1%
`0.0%
`0.0%
`0.2%
`
`5.8%
`0.4%
`1.9%
`8.1%
`5.4%
`0.9%
`0.2%
`
`0.2%
`1.5%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.1%
`0.6%
`2.5%
`2.6%
`0.1%
`0.0%
`0.0%
`0.2%
`
`5.8%
`0.4%
`1.9%
`8.1%
`5.5%
`0.9%
`0.2%
`
`0.2%
`1.5%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.1%
`0.6%
`2.5%
`2.6%
`0.2%
`0.0%
`0.0%
`0.2%
`
`5.7%
`0.4%
`1.9%
`8.1%
`5.5%
`0.9%
`0.2%
`
`0.2%
`1.4%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.1%
`0.6%
`2.4%
`2.6%
`0.2%
`0.0%
`0.0%
`0.2%
`
`5.7%
`0.4%
`1.9%
`8.0%
`5.5%
`0.9%
`0.2%
`
`0.2%
`1.4%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.1%
`0.5%
`2.4%
`2.7%
`0.2%
`0.0%
`0.0%
`0.3%
`
`5.7%
`0.4%
`1.9%
`8.0%
`5.5%
`0.9%
`0.2%
`
`0.2%
`1.4%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.1%
`0.5%
`2.4%
`2.7%
`0.3%
`0.0%
`0.0%
`0.3%
`
`5.6%
`0.4%
`1.9%
`7.9%
`5.6%
`0.9%
`0.2%
`
`0.2%
`1.4%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.1%
`0.5%
`2.3%
`2.7%
`0.3%
`0.0%
`0.0%
`0.3%
`
`5.6%
`0.4%
`1.9%
`7.9%
`5.6%
`0.9%
`0.2%
`
`0.2%
`1.4%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.1%
`0.2%
`
`5.9%
`0.5%
`1.9%
`8.3%
`5.2%
`0.8%
`0.2%
`
`0.3%
`1.6%
`0.8%
`0.0%
`0.0%
`0.0%
`0.3%
`
`0.0%
`0.0%
`0.2%
`
`5.8%
`0.4%
`1.9%
`8.1%
`5.4%
`0.9%
`0.2%
`
`0.2%
`1.5%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.0%
`0.0%
`0.2%
`
`5.6%
`0.4%
`1.8%
`7.8%
`5.9%
`1.0%
`0.2%
`
`0.2%
`1.4%
`0.8%
`0.0%
`0.0%
`0.0%
`0.2%
`
`0.1%
`0.1%
`0.2%
`
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.4%
`0.7%
`0.9%
`0.5%
`0.5%
`0.5%
`0.5%
`0.6%
`0.6%
`0.6%
`0.7%
`0.7%
`0.7%
`0.8%
`0.9%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`0.0%
`100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
`
`
`
`Source: Company reports, IMS database and UBS estimates
`
` U.S. Pharmaceuticals 6 April 2018
`
`
`
` 47
`
`Mylan Ex.1089
`Mylan v. Sanofi - IPR2018-01676
`
`

`

`
`
`Figure 46: Endocrinology – Diabetes (Non-Insulin) TRx Growth Rates
`
`2017
`
`Jan-18
`
`Feb-18 Mar-18E
`
`Apr-18E May-18E
`
`Jun-18E
`
`Jul-18E
`
`Aug-18E
`
`Sep-18E
`
`Oct-18E
`
`Nov-18E
`
`Dec-18E
`
`2018E
`
`2019E
`
`-3.3%
`
`-2.6%
`
`-3.7%
`
`2.5%
`
`2.8%
`
`2.8%
`
`3.7%
`
`3.3%
`
`3.5%
`
`4.4%
`
`4.6%
`
`4.7%
`
`5.0%
`
`2.6%
`
`-48.3%
`-29.6%
`-8.1%
`-3.4%
`
`-52.7%
`-19.6%
`-8.7%
`-3.5%
`
`-49.4%
`-43.5%
`-9.4%
`-5.3%
`
`-43.5%
`-35.6%
`-3.8%
`-0.3%
`
`-25.3%
`-31.1%
`-2.9%
`0.3%
`
`-27.6%
`-26.5%
`-2.3%
`0.7%
`
`-22.9%
`-15.6%
`-0.7%
`0.6%
`
`-6.6%
`-21.6%
`0.1%
`2.1%
`
`-10.3%
`-9.5%
`0.7%
`1.5%
`
`-3.6%
`-15.6%
`1.1%
`1.7%
`
`-1.7%
`-20.4%
`0.2%
`0.1%
`
`-5.0%
`-11.4%
`-0.5%
`0.4%
`
`3.0%
`-5.8%
`1.2%
`1.1%
`
`-25.2%
`-22.7%
`-2.1%
`-0.1%
`
`1.4%
`
`-0.6%
`
`-1.9%
`
`2.6%
`
`2.6%
`
`3.2%
`
`3.4%
`
`3.5%
`
`3.9%
`
`4.2%
`
`4.5%
`
`4.8%
`
`4.8%
`
`2.9%
`
`-31.3%
`4.1%
`2.2%
`
`-32.4%
`-4.3%
`3.4%
`
`-30.6%
`-2.1%
`2.0%
`
`-24.6%
`1.3%
`6.8%
`
`-17.2%
`4.7%
`7.0%
`
`-25.2%
`6.1%
`6.5%
`
`-16.0%
`3.8%
`6.6%
`
`-22.7%
`9.3%
`6.5%
`
`-13.4%
`8.8%
`6.4%
`
`-8.4%
`2.8%
`6.0%
`
`-6.9%
`9.1%
`5.4%
`
`-10.4%
`1.9%
`5.8%
`
`0.4%
`-0.7%
`5.2%
`
`-18.4%
`3.3%
`5.7%
`
`-3.2%
`
`-1.3%
`
`-3.0%
`
`9.6%
`
`9.7%
`
`8.6%
`
`9.5%
`
`11.7%
`
`7.7%
`
`-32.1%
`
`-31.6%
`
`-32.4%
`
`-31.6%
`
`-6.0%
`
`0.4%
`
`4.6%
`2.2%
`4.0%
`3.9%
`
`4.7%
`
`3.5%
`4.0%
`4.0%
`
`6.2%
`
`-99.4%
`67.7%
`-13.5%
`1.1%
`13.4%
`11.7%
`
`TRx Growth Rate
`Sulfonylureas
`Total Sulfonylureas
`Glinides,alone
`Prandin - Novo Nordisk
`Starlix - Novartis
`Generic Starlix - (Nateglinide)
`Total Glinides
`Biguanides, alone (metformin)
`Total Biguanides
`Glitazone,alone
`Actos - Takeda
`Avandia - GSK
`Total Glitazone,alone
`Alpha-Glucos Inhibitor,alone
`Total Alpha-Glucos Inhib
`Human GLP-1 Analogs
`Byetta - AstraZeneca
`Generic Byetta - Teva
`Bydureon - AstraZeneca
`Victoza - Novo Nordisk
`Trulicity (Dulaglutide) - Lilly
`Total human GLP-1 analogs
`DPP-4 Inhibitor,alone
`Januvia - Merck
`Tradjenta - LLY/BI
`Total DPP-4 Inhibitor
`Total SGLT-2 Inhibitor
`Total SGLT-2INHIB/Biguanide combo
`Glitazone/Biguanide comb
`Actoplus Met - Takeda
`Generic Actoplus Met (Pioglit/Metformin)
`Actoplus Met XR - Takeda
`Avandamet - GSK
`Glitazone comb
`Total Glitazone comb
`DPP-4INHIB/Biguanide comb
`Jantadueto - BI
`Janumet - Merck
`Janumet XR - Merck
`Juvisync - Merck
`Kazano - Takeda
`Oseni - Takeda
`Kombiglyze XR - AstraZeneca
`Total DPP-4 INHIB/Biguanide
`Total SGLT-2/DPP-IV Combo
`Glinide/Biguanide comb
`Prandimet - Novo Nordisk
`Generic Prandimet
`Biguanide/sulfonylurea comb
`Dopamine Receptor
`Cycloset - Vero Science
`Total Human Amylin Analogs
`Total
`
`-18.9%
`NM
`5.7%
`7.7%
`NM
`24.2%
`
`2.2%
`7.6%
`1.0%
`12.6%
`27.4%
`
`-46.2%
`-17.8%
`-21.1%
`-96.0%
`-19.7%
`-41.8%
`
`-7.0%
`-7.0%
`-4.5%
`7.6%
`-100.0%
`-49.2%
`-26.0%
`-5.4%
`-12.3%
`
`-20.6%
`NM
`5.2%
`14.0%
`79.9%
`28.7%
`
`3.5%
`4.3%
`1.4%
`10.0%
`7.9%
`
`-37.3%
`-18.3%
`-22.2%
`NM
`-20.5%
`-47.3%
`
`-13.4%
`-13.4%
`-2.6%
`6.6%
`NM
`-45.5%
`-28.2%
`-4.4%
`-6.9%
`
`-24.9%
`NM
`6.7%
`13.5%
`70.0%
`26.7%
`
`1.5%
`2.5%
`-0.4%
`7.9%
`2.8%
`
`-41.4%
`-19.4%
`-22.6%
`NM
`-20.7%
`-36.1%
`
`-16.6%
`-16.6%
`-4.6%
`4.6%
`NM
`-46.9%
`-29.6%
`-6.3%
`-8.3%
`
`-45.2%
`NM
`5.1%
`11.7%
`61.5%
`24.3%
`
`5.0%
`8.1%
`3.7%
`11.1%
`15.1%
`
`-32.9%
`-15.4%
`-12.3%
`NM
`-15.2%
`-12.7%
`
`-8.4%
`-8.4%
`-1.8%
`8.4%
`NM
`-42.5%
`-25.2%
`-2.5%
`2.2%
`
`-52.4%
`NM
`4.1%
`10.1%
`54.6%
`22.7%
`
`4.0%
`7.1%
`3.0%
`10.0%
`16.3%
`
`-31.3%
`-12.9%
`1.4%
`NM
`-12.0%
`-5.9%
`
`-6.0%
`-6.0%
`-2.2%
`7.6%
`NM
`-38.0%
`-20.9%
`-2.0%
`12.1%
`
`-61.0%
`NM
`0.9%
`7.1%
`46.8%
`19.2%
`
`3.2%
`5.6%
`2.3%
`8.3%
`14.7%
`
`-17.6%
`-10.8%
`13.3%
`NM
`-9.3%
`-3.5%
`
`-7.4%
`-7.4%
`-2.9%
`6.4%
`NM
`-35.4%
`-20.2%
`-2.7%
`16.2%
`
`-98.4% -100.0% -100.0% -100.0%
`-66.7%
`-93.8%
`-93.1%
`-91.0%
`-13.7%
`-12.9%
`-14.3%
`-20.0%
`
`NM -100.0%
`-89.4%
`-84.4%
`-18.1%
`-16.7%
`
`-21.4%
`-22.3%
`1.6%
`
`-7.2%
`-17.4%
`0.9%
`
`-3.1%
`-23.0%
`-0.4%
`
`9.6%
`-15.9%
`4.0%
`
`9.6%
`-10.3%
`4.0%
`
`14.0%
`-18.1%
`4.0%
`
`-68.7%
`NM
`-0.9%
`5.4%
`42.5%
`17.4%
`
`2.5%
`5.0%
`1.7%
`7.6%
`16.1%
`
`-25.0%
`-9.6%
`18.4%
`NM
`-8.1%
`-5.1%
`
`-7.1%
`-7.1%
`-4.1%
`6.1%
`NM
`-32.0%
`-19.7%
`-3.3%
`21.9%
`
`NM
`-80.4%
`-27.4%
`
`13.3%
`-18.2%
`4.0%
`
`-75.2%
`NM
`-1.4%
`5.2%
`38.1%
`16.9%
`
`1.4%
`3.3%
`0.8%
`8.1%
`20.3%
`
`-20.9%
`-6.5%
`38.6%
`NM
`-3.7%
`8.1%
`
`-5.9%
`-5.9%
`-4.6%
`5.8%
`NM
`-30.6%
`-16.4%
`-3.1%
`28.3%
`
`NM
`-70.8%
`-26.9%
`
`11.0%
`-15.8%
`4.0%
`
`-83.2%
`NM
`-3.5%
`2.4%
`32.1%
`14.0%
`
`0.6%
`2.1%
`0.0%
`7.9%
`21.8%
`
`-11.0%
`-6.6%
`47.5%
`NM
`-2.8%
`25.6%
`
`-6.8%
`-6.8%
`-5.9%
`3.4%
`NM
`-25.9%
`-15.0%
`-4.4%
`32.3%
`
`NM
`-56.9%
`-25.8%
`
`12.3%
`-11.1%
`4.0%
`
`-86.9%
`NM
`-5.5%
`-0.4%
`28.4%
`12.1%
`
`-0.5%
`1.8%
`-0.7%
`8.1%
`23.3%
`
`-20.6%
`-4.9%
`55.2%
`NM
`-1.4%
`5.9%
`
`-6.1%
`-6.1%
`-6.8%
`2.2%
`NM
`-25.0%
`-14.4%
`-5.0%
`37.3%
`
`NM
`-53.6%
`-37.3%
`
`5.1%
`-14.0%
`4.0%
`
`-90.7%
`NM
`-7.7%
`-3.2%
`24.5%
`9.7%
`
`-0.9%
`0.9%
`-1.2%
`8.0%
`24.6%
`
`-22.4%
`-5.2%
`67.0%
`NM
`-1.2%
`6.4%
`
`-5.7%
`-5.7%
`-8.1%
`1.9%
`NM
`-21.0%
`-13.6%
`-5.6%
`42.5%
`
`NM
`-31.8%
`-36.5%
`
`7.6%
`-8.0%
`4.0%
`
`-95.9%
`NM
`-10.2%
`-6.9%
`21.1%
`7.2%
`
`-1.1%
`0.1%
`-1.4%
`7.5%
`23.9%
`
`-13.0%
`-2.5%
`86.8%
`NM
`2.4%
`11.3%
`
`-5.3%
`-5.3%
`-9.3%
`0.8%
`NM
`-23.6%
`-12.1%
`-6.5%
`46.1%
`
`NM
`-53.3%
`-35.9%
`
`-2.0%
`-11.3%
`4.0%
`
`-99.8%
`NM
`-11.0%
`-10.1%
`18.4%
`5.4%
`
`-1.0%
`0.5%
`-1.2%
`7.2%
`25.0%
`
`-9.2%
`-2.6%
`88.9%
`NM
`2.5%
`11.1%
`
`-5.2%
`-5.2%
`-9.9%
`0.1%
`NM
`-19.3%
`-11.7%
`-6.9%
`52.9%
`
`NM
`65.1%
`-35.2%
`
`0.3%
`-13.4%
`4.0%
`
`-65.8%
`NM
`-1.6%
`3.8%
`40.0%
`16.5%
`
`1.5%
`3.5%
`0.7%
`8.5%
`17.8%
`
`-25.0%
`-9.9%
`27.3%
`NM
`-8.0%
`-8.2%
`
`-7.9%
`-7.9%
`-5.2%
`4.5%
`NM
`-33.5%
`-19.4%
`-4.4%
`22.6%
`
`-100.0%
`-83.9%
`-25.2%
`
`5.7%
`-14.8%
`3.4%
`
`0.1%
`1.4%
`0.0%
`11.7%
`21.7%
`
`2.4%
`3.8%
`90.4%
`NM
`9.7%
`4.5%
`
`0.3%
`0.3%
`-3.8%
`1.6%
`NM
`74.6%
`-17.8%
`-2.6%
`50.0%
`
`NM
`3.5%
`-43.0%
`
`4.4%
`4.1%
`4.0%
`
`
`
`Source: Company reports, IMS database and UBS estimates
`
` U.S. Pharmaceuticals 6 April 2018
`
`
`
` 48
`
`Mylan Ex.1089
`Mylan v. Sanofi - IPR2018-01676
`
`

`

`
`
`Figure 47: Endocrinology – Diabetes (Non-Insulin) Promotion Details Monthly
`
`# of Details for Tot. Category ('000s)
`
`Total Category
`Growth rate
`
`Jan-17
`2016
`349
`3,819
`-8.5% -6.0%
`
`Feb-17
`312
`-4.3%
`
`Mar-17
`302
`-17.8%
`
`Apr-17
`307
`9.5%
`
`May-17
`277
`-9.3%
`
`Jun-17
`319
`-3.8%
`
`Jul-17
`266
`-23.3%
`
`Aug-17
`276
`-2.1%
`
`Sep-17
`288
`-6.6%
`
`Oct-17
`337
`0.1%
`
`Nov-17
`362
`30.8%
`
`Dec-17
`266
`-6.9%
`
`Jan-18 YTD 2018
`2017
`279
`552
`3,662
`-4.1% -20.2%
`58.1%
`
`2016
`
`Jan-17
`
`Feb-17
`
`Mar-17
`
`Apr-17
`
`May-17
`
`Jun-17
`
`Jul-17
`
`Aug-17
`
`Sep-17
`
`Oct-17
`
`Nov-17
`
`Dec-17
`
`2017
`
`Jan-18 YTD 2018
`
`0.0%
`
`0.1%
`
`0.0%
`
`0.0%
`
`0.0%
`
`0.1%
`
`0.0%
`0.0%
`
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`
`0.0%
`0.0%
`
`Market Share
`Sulfonylureas
`Total Sulfonylureas
`Glinides,alone
`Prandin - Novo Nordisk
`Starlix - Novartis
`Biguanides, alone (Metformin)
`Total Biguanides
`Actos - Takeda
`Avandia - GlaxoSmithkline
`Total Alpha-Glucos Inhibitors
`Byetta - AstraZeneca
`Bydureon - AstraZeneca
`Victoza - Novo Nordisk
`Tanzeum - GSK
`Trulicity (Dulaglutide) - Lilly
`
`0.1%
`0.0%
`0.0%
`0.0%
`0.5%
`4.8%
`5.9%
`3.7%
`
`6.6%
`
`10.2%
`
`12.3%
`2.8%
`6.4%
`
`0.0%
`0.0%
`
`0.3%
`0.0%
`0.0%
`0.0%
`0.1%
`4.1%
`5.2%
`0.4%
`
`6.4%
`
`6.8%
`
`0.0%
`0.0%
`
`0.1%
`0.0%
`0.0%
`0.0%
`0.8%
`3.7%
`7.7%
`0.6%
`
`8.8%
`
`9.4%
`
`0.0%
`0.0%
`
`0.7%
`0.0%
`0.0%
`0.0%
`0.3%
`4.6%
`9.1%
`0.6%
`
`7.1%
`
`7.7%
`
`0.0%
`0.0%
`
`0.5%
`0.1%
`0.1%
`0.0%
`0.1%
`4.7%
`4.3%
`0.4%
`
`5.9%
`
`6.3%
`
`0.0%
`0.0%
`
`0.1%
`0.2%
`0.0%
`0.0%
`0.1%
`3.1%
`7.5%
`0.4%
`
`7.3%
`
`7.7%
`
`0.0%
`0.1%
`0.0%
`0.0%
`0.2%
`3.6%
`3.8%
`0.3%
`
`8.4%
`
`8.7%
`
`0.1%
`0.1%
`0.0%
`0.0%
`1.0%
`5.1%
`6.7%
`0.5%
`
`8.8%
`
`9.3%
`
`0.1%
`0.2%
`0.0%
`0.0%
`0.5%
`4.2%
`6.5%
`0.1%
`
`7.9%
`
`8.0%
`
`0.4%
`0.1%
`0.0%
`0.0%
`0.1%
`3.9%
`6.4%
`0.0%
`
`6.2%
`
`6.2%
`
`0.1%
`0.1%
`0.0%
`0.0%
`0.3%
`5.0%
`9.2%
`0.1%
`
`8.7%
`
`8.7%
`
`0.1%
`0.3%
`0.0%
`0.0%
`0.1%
`5.6%
`10.9%
`0.1%
`
`8.0%
`
`8.1%
`
`0.1%
`0.1%
`0.1%
`0.0%
`0.1%
`3.2%
`11.4%
`0.1%
`
`10.8%
`
`10.9%
`
`0.2%
`0.1%
`0.0%
`0.0%
`0.3%
`4.3%
`7.4%
`0.3%
`
`7.8%
`
`8.1%
`
`14.0%
`1.8%
`4.6%
`
`0.1%
`0.1%
`0.0%
`0.0%
`0.1%
`3.9%
`7.7%
`0.0%
`
`11.2%
`
`11.2%
`
`0.1%
`0.2%
`0.0%
`0.0%
`0.1%
`3.9%
`8.0%
`0.0%
`
`10.9%
`
`10.9%
`
`12.0%
`1.6%
`5.4%
`
`12.4%
`1.5%
`4.9%
`
`8.1%
`19.5%
`14.5%
`
`0.6%
`0.9%
`0.0%
`
`18.2%
`1.7%
`4.9%
`
`9.1%
`16.2%
`15.9%
`
`2.7%
`1.6%
`0.1%
`
`10.8%
`19.0%
`10.0%
`
`2.2%
`0.9%
`0.1%
`
`13.9%
`2.1%
`5.6%
`
`12.2%
`14.6%
`13.6%
`
`1.6%
`0.4%
`0.2%
`
`0.4%
`0.3%
`5.2%
`4.9%
`0.5%
`11.2%
`
`9.5%
`1.6%
`3.0%
`
`10.4%
`22.9%
`19.8%
`
`0.9%
`0.0%
`0.0%
`
`2.1%
`0.2%
`3.0%
`6.3%
`0.3%
`11.9%
`
`15.3%
`2.2%
`4.6%
`
`10.6%
`18.5%
`14.3%
`
`1.5%
`0.0%
`0.0%
`
`0.5%
`0.1%
`5.6%
`5.5%
`0.3%
`12.0%
`
`14.5%
`2.1%
`3.3%
`
`19.5%
`20.4%
`12.4%
`
`1.7%
`0.0%
`0.3%
`
`0.3%
`0.2%
`3.5%
`3.8%
`0.0%
`7.8%
`
`18.7%
`1.4%
`3.5%
`
`12.3%
`13.8%
`13.6%
`
`1.4%
`0.0%
`0.0%
`
`0.5%
`0.3%
`4.0%
`5.2%
`0.4%
`10.4%
`
`12.0%
`2.7%
`4.2%
`
`17.4%
`13.2%
`18.2%
`
`0.7%
`0.0%
`0.0%
`
`0.4%
`0.1%
`4.6%
`3.4%
`0.4%
`9.0%
`
`15.3%
`2.1%
`5.4%
`
`15.0%
`18.3%
`14.2%
`
`1.1%
`0.0%
`0.1%
`
`1.9%
`0.0%
`3.1%
`4.6%
`0.5%
`10.1%
`
`14.4%
`1.1%
`3.8%
`
`13.4%
`14.1%
`16.7%
`
`1.0%
`0.3%
`0.0%
`
`0.7%
`0.0%
`3.2%
`4.9%
`0.1%
`9.0%
`
`11.7%
`1.0%
`5.5%
`
`11.1%
`22.5%
`11.6%
`
`0.3%
`0.9%
`0.0%
`
`0.4%
`0.1%
`5.3%
`2.1%
`0.7%
`8.6%
`
`12.5%
`2.0%
`6.5%
`
`13.6%
`13.8%
`17.2%
`
`1.3%
`0.2%
`0.0%
`
`0.0%
`0.0%
`1.7%
`3.8%
`0.3%
`5.8%
`
`12.6%
`17.5%
`15.1%
`
`1.2%
`0.4%
`0.1%
`
`0.9%
`0.1%
`4.4%
`4.5%
`0.3%
`10.4%
`
`12.8%
`1.6%
`5.8%
`
`16.3%
`18.6%
`12.6%
`
`0.9%
`0.8%
`0.0%
`
`0.3%
`0.1%
`4.7%
`2.3%
`0.1%
`7.4%
`
`15.3%
`17.2%
`15.4%
`
`0.8%
`0.6%
`0.0%
`
`0.2%
`0.1%
`4.3%
`2.9%
`0.1%
`7.6%
`
`Other human GLP-1 analogs
`DPP-4 Inhibitor,alone
`Januvia - Merck
`Onglyza - AstraZeneca
`Tradjenta - Lilly
`SGLT-2 Inhibitor
`Farxiga - AstraZeneca
`Invokana/Invokamet - J&J
`Jardiance - Lilly/BI
`SGLT-2INHIB/Biguanide combo
`Xigduo XR - AstraZeneca
`Synjardy - Lilly/BI
`Glitazone comb
`DPP-4INHIB/Biguanide comb
`Jentadueto - Lilly/BI
`Kazano - Takeda
`Janumet - Merck
`Janumet XR - Merck
`Kombiglyze XR - AstraZeneca
`Total DPP-4INHIB/Biguanide
`SGLT-2/DPP-IV Combo
`Glyxambi - Lilly/BI
`Glinide/Biguanide comb
`Prandimet - Novo Nordisk
`Biguanide/sulfonylurea comb
`Human Amylin analogs
`Total Human Amylin analogs
`Total
`
`Source: IMS database
`
`1.3%
`0.4%
`4.7%
`2.8%
`0.8%
`10.0%
`
`4.2%
`
`0.0%
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`0.0%
`
`0.0%
`0.0%
`
`0.1%
`100.0%
`
`0.0%
`100.0%
`
`0.1%
`100.0%
`
`0.0%
`100.0%
`
`0.0%
`100.0%
`
`0.1%
`100.0%
`
`0.0%
`100.0%
`
`0.0%
`100.0%
`
`0.0%
`100.0%
`
`3.6%
`0.2%
`9.1%
`6.7%
`0.4%
`20.0%
`
`0.1%
`0.3%
`3.6%
`3.2%
`0.3%
`7.4%
`
`1.9%
`
`1.9%
`
`2.5%
`
`3.9%
`
`2.0%
`
`1.6%
`
`2.4%
`
`2.9%
`
`1.3%
`
`2.6%
`
`1.7%
`
`1.1%
`
`0.0%
`0.0%
`
`0.1%
`100%
`
`0.0%
`0.0%
`
`0.0%
`100%
`
`0.0%
`0.0%
`
`0.0%
`100%
`
`0.0%
`0.0%
`
`0.0%
`100%
`
`2.2%
`
`0.0%
`0.0%
`
`0.8%
`
`0.0%
`0.0%
`
`1.4%
`
`0.0%
`0.0%
`
`0.0%
`100%
`
`0.1%
`100.0%
`
`0.0%
`100.0%
`
`
`
` U.S. Pharmaceuticals 6 April 2018
`
`
`
` 49
`
`Mylan Ex.1089
`Mylan v. Sanofi - IPR2018-01676
`
`

`

`
`
`Figure 48: Endocrinology – Diabetes DPP-IV Inhibitors Monthly
`
`TRx
`Total TRxs
`DPP-IV Market Growth Rate
`% of Total Diabetes Market
`
`2019E
`2018E
`Dec-18E
`Nov-18E
`Oct-18E
`Sep-18E
`Aug-18E
`Jul-18E
`Jun-18E
`Apr-18E May-18E
`Feb-18 Mar-18E
`Jan-18
`2017
`19,507,374 1,672,459 1,482,267 1,739,405 1,609,822 1,715,568 1,666,432 1,621,894 1,660,169 1,555,316 1,625,854 1,550,274 1,559,481 19,458,941 19,534,493
`-1.0%
`-0.2%
`0.4%
`-0.3%
`-2.1%
`2.1%
`1.8%
`1.2%
`0.8%
`0.2%
`-0.6%
`-1.2%
`-1.6%
`-1.9%
`-1.7%
`11.5%
`11.1%
`10.7%
`11.5%
`11.3%
`11.3%
`11.2%
`11.2%
`11.1%
`11.1%
`11.0%
`11.0%
`10.9%
`10.9%
`10.8%
`
`Market Share
`Januvia - Merck
`Onglyza - Astra Zeneca
`Nesina - Takeda
`Tradjenta - Lilly/BI
`Combination Drugs
`Jentadueto - Lilly/BI
`Janumet - Merck
`Janumet XR - Merck
`Kazano - Takeda
`Oseni - Takeda
`Kombiglyze XR - Astra Zeneca
`SGLT-2/DPP-IV Combo
`Qtern (Dapagliflozin/Onglyza) - AstraZeneca
`Steglujan (Steglatro/Januvia combo) - PFE/MRK
`Glyxanbi - Lilly/BI
`Total TRxs
`
`Januvia - Merck
` TRxs
` Sales
` Price/Rx
`
`2017
`51.1%
`4.6%
`0.2%
`16.4%
`
`2.2%
`14.0%
`7.2%
`0.1%
`0.2%
`2.3%
`
`Jan-18
`52.2%
`3.9%
`0.1%
`16.8%
`
`2.0%
`13.8%
`7.4%
`0.1%
`0.1%
`1.9%
`
`Feb-18 Mar-18E
`52.2%
`52.2%
`3.8%
`3.8%
`0.1%
`0.1%
`16.9%
`16.9%
`
`Apr-18E May-18E
`52.1%
`52.1%
`3.8%
`3.8%
`0.1%
`0.1%
`17.0%
`17.0%
`
`2.0%
`13.7%
`7.6%
`0.1%
`0.1%
`1.9%
`
`2.0%
`13.6%
`7.5%
`0.1%
`0.1%
`1.9%
`
`2.0%
`13.5%
`7.5%
`0.1%
`0.1%
`1.9%
`
`2.0%
`13.4%
`7.6%
`0.1%
`0.1%
`1.9%
`
`Jun-18E
`52.1%
`3.8%
`0.1%
`17.0%
`
`2.0%
`13.3%
`7.6%
`0.1%
`0.1%
`1.9%
`
`Jul-18E
`52.0%
`3.8%
`0.1%
`17.1%
`
`2.0%
`13.2%
`7.6%
`0.1%
`0.1%
`1.9%
`
`Aug-18E
`52.0%
`3.8%
`0.1%
`17.1%
`
`Sep-18E
`52.0%
`3.8%
`0.1%
`17.1%
`
`Oct-18E
`52.0%
`3.8%
`0.1%
`17.1%
`
`Nov-18E
`51.9%
`3.8%
`0.1%
`17.2%
`
`Dec-18E
`51.9%
`3.8%
`0.1%
`17.2%
`
`2.0%
`13.1%
`7.6%
`0.1%
`0.1%
`1.9%
`
`2.0%
`13.0%
`7.6%
`0.1%
`0.1%
`1.9%
`
`2.0%
`12.9%
`7.6%
`0.1%
`0.1%
`1.9%
`
`2.0%
`12.8%
`7.6%
`0.1%
`0.1%
`1.9%
`
`2.0%
`12.7%
`7.6%
`0.1%
`0.1%
`1.9%
`
`2018E
`52.1%
`3.8%
`0.1%
`17.0%
`
`2.0%
`13.3%
`7.6%
`0.1%
`0.1%
`1.9%
`
`2019E
`51.9%
`3.6%
`0.1%
`17.2%
`
`2.0%
`12.7%
`7.7%
`0.2%
`0.1%
`1.5%
`
`0.0%
`0.3%
`0.3%
`0.3%
`0.2%
`0.2%
`0.2%
`0.2%
`0.1%
`0.1%
`0.1%
`0.0%
`0.0%
`0.0%
`0.5%
`0.5%
`0.4%
`0.4%
`0.3%
`0.3%
`0.2%
`0.2%
`0.1%
`0.1%
`0.0%
`0.0%
`1.7%
`1.7%
`1.7%
`1.7%
`1.7%
`1.7%
`1.7%
`1.7%
`1.6%
`1.6%
`1.6%
`1.6%
`1.6%
`100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
`I
`I
`
`2017
`
`1Q18E
`
`2Q18E
`
`3Q18E
`
`4Q18E
`
`0.2%
`0.2%
`1.7%
`100.0%
`
`0.5%
`0.8%
`1.8%
`100.0%
`
`2018E
`
`2019E
`
`9,976,644
`$2,154.0
`$219.91
`
`2,601,031
`$562.9
`$216.43
`
`2,516,241
`$608.3
`$241.75
`
`2,459,042 10,130,396 10,137,659
`$509.0
`$2,248.1
`$2,182.0
`$221.92
`$215.23
`$207.01
`
`YOY Price Change:
`
`1.2%
`
`YOY Price Change:
`
`1.2%
`
`-3.0%
`
`Price Increase (1/5/2018):
`YOY Price Change:
`
`-3.1%
`
`YOY Price Change:
`
`Janumet - Merck
` TRxs
` Sales
` Price/Rx
`
`Janumet XR - Merck
` TRxs
` Sales
` Price/Rx
`
`2017
`
`2,721,833
`$618.4
`$251.10
`-0.5%
`
`2017
`
`1,409,266
`$268.1
`$190.24
`-4.1%
`
`Source: Company reports, IMS database and UBS estimates
`
` U.S. Pharmaceuticals 6 April 2018
`
`2,554,082
`$567.8
`$222.32
`8.0%
`0.4%
`
`1Q18E
`
`670,301
`$148.0
`$220.80
`-4.0%
`
`YOY Price Change:
`
`0.8%
`
`2Q18E
`
`669,394
`$170.3
`$254.40
`-4.0%
`
`3Q18E
`
`634,293
`$155.2
`$244.61
`-4.0%
`
`YOY Price Change:
`
`YOY Price Change:
`
`0.9%
`
`4Q18E
`
`2018E
`
`2019E
`
`606,743
`$148.4
`$244.61
`-4.0%
`
`2,580,732
`$621.9
`$240.96
`-4.0%
`
`2,483,021
`$581.0
`$233.99
`-2.9%
`
`YOY Price Change:
`
`I
`
`I
`1Q18E
`
`I
`
`I
`2Q18E
`
`I
`
`I
`3Q18E
`
`I
`
`4Q18E
`
`2018E
`
`2019E
`
`367,446
`$67.7
`$184.32
`-4.0%
`
`YOY Price Change:
`
`377,332
`$66.6
`$176.40
`-4.0%
`
`YOY Price Change:
`
`367,097
`$60.3
`$164.30
`-4.0%
`
`YOY Price Change:
`
`YOY Price Change:
`
`360,794
`$74.1
`$205.32
`-4.0%
`
`1,472,669
`$268.7
`$182.45
`-4.1%
`
`1,496,699
`$264.9
`$176.97
`-3.0%
`
`
`
`
`
` 50
`
`Mylan Ex.1089
`Mylan v. Sanofi - IPR2018-01676
`
`

`

`
`
`Tradjenta - Lilly/BI
` TRxs
` Sales
` Price/Rx
`
`Figure 49: Endocrinology – Diabetes DPP-IV Inhibitors Monthly Continued
`1-- I
`1Q18E
`826,268
`$247.9
`$300.00
`9.1%
`
`2017
`
`3,203,318
`$1,044.9
`$350.70
`27.9%
`
`YOY Price Change:
`
`1-- I
`2Q18E
`848,199
`$254.5
`$300.00
`-22.3%
`
`YOY Price Change:
`
`1-- I
`3Q18E
`826,273
`$247.9
`$300.00
`-23.1%
`
`YOY Price Change:
`
`I
`
`4Q18E
`
`2018E
`
`2019E
`
`YOY Price Change:
`
`YOY Price Change:
`
`YOY Price Change:
`
`813,152
`$243.9
`$300.00
`-14.3%
`
`3,313,891
`$994.2
`$300.00
`-14.5%
`
`3,360,211
`$1,008.1
`$300.00
`0.0%
`
`4Q18E
`
`2018E
`
`2019E
`
`96,468
`$27.3
`$283.47
`3.1%
`
`396,566
`$112.4
`$283.47
`3.1%
`
`397,934
`$116.1
`$291.83
`3.0%
`
`4Q18E
`
`2018E
`
`2019E
`
`80,599
`$38.5
`$477.39
`2.7%
`
`322,221
`$153.8
`$477.39
`2.7%
`
`344,227
`$168.4
`$489.33
`2.5%
`
`$309.8
`
`$1,260.4
`
`$1,292.6
`
`
`
`Jentadueto - Lilly/BI
` TRxs
` Sales
` Price/Rx
`
`Glyxambi - Lilly/BI
` TRxs
` Sales
` Price/Rx
`
`Total Tradjenta Franchise
`
`2017
`
`430,719
`$118.5
`$275.08
`23.3%
`
`2017
`
`324,684
`$151.0
`$465.00
`0.8%
`
`$1,314.4
`
`1Q18E
`
`99,869
`$28.3
`$283.47
`3.1%
`
`1Q18E
`
`78,763
`$37.6
`$477.39
`2.7%
`
`$313.8
`
`YOY Price Change:
`
`YOY Price Change:
`
`2Q18E
`
`101,688
`$28.8
`$283.47
`3.1%
`
`2Q18E
`
`81,978
`$39.1
`$477.39
`2.7%
`
`$322.4
`
`3Q18E
`
`98,541
`$27.9
`$283.47
`3.1%
`
`3Q18E
`
`80,880
`$38.6
`$477.39
`2.7%
`
`$314.4
`
`YOY Price Change:
`
`YOY Price Change:
`
`YOY Price Change:
`
`YOY Price Change:
`
`Source: Company reports, IMS database and UBS estimates
`
`
`
`
`
` U.S. Pharmaceuticals 6 April 2018
`
`
`
` 51
`
`Mylan Ex.1089
`Mylan v. Sanofi - IPR2018-01676
`
`

`

`
`
`Figure 50: Endocrinology – Diabetes DPP-IV Inhibitors TRx Growth Rates
`
`TRx Growth Rate
`Januvia - Merck
`Onglyza - AstraZeneca
`Nesina - Takeda
`Tradjenta - Lilly/BI
`Combination Drugs
`Jentadueto - Lilly/BI
`Janumet - Merck
`Janumet XR - Merck
`Kazano - Takeda
`Oseni - Takeda
`Kombiglyze XR - AstraZeneca
`SGLT-2/DPP-IV Combo
`Qtern (Dapagliflozin/Onglyza) - AstraZeneca
`Steglujan (Steglatro/Januvia combo) - PFE/MRK
`Glyxanbi - Lilly/BI
`Total
`
`2017
`2.2%
`-23.3%
`-42.7%
`7.6%
`
`-7.0%
`-4.5%
`7.6%
`-49.2%
`-59.1%
`-26.0%
`
`NM
`NM
`-12.3%
`-1.0%
`
`Jan-18
`3.5%
`-25.0%
`-50.4%
`4.3%
`
`-13.4%
`-2.6%
`6.6%
`-45.5%
`NM
`-28.2%
`
`NM
`NM
`-7.0%
`-0.3%
`
`Feb-18 Mar-18E
`1.5%
`5.0%
`-26.0%
`-21.2%
`-50.1%
`-47.9%
`2.5%
`8.1%
`
`Apr-18E May-18E
`4.0%
`3.2%
`-19.0%
`-17.8%
`-44.6%
`-41.5%
`7.1%
`5.6%
`
`-16.6%
`-4.6%
`4.6%
`-46.9%
`NM
`-29.6%
`
`NM
`NM
`-9.0%
`-2.1%
`
`-8.4%
`-1.8%
`8.4%
`-42.5%
`-49.1%
`-25.2%
`
`NM
`NM
`-3.8%
`2.1%
`
`-6.0%
`-2.2%
`7.6%
`-38.0%
`-44.0%
`-20.9%
`
`NM
`NM
`0.3%
`1.8%
`
`-7.4%
`-2.9%
`6.4%
`-35.4%
`-43.0%
`-20.2%
`
`NM
`NM
`-0.3%
`1.2%
`
`Jun-18E
`2.5%
`-17.1%
`-41.5%
`5.0%
`
`-7.1%
`-4.1%
`6.1%
`-32.0%
`-39.9%
`-19.7%
`
`NM
`NM
`0.5%
`0.8%
`
`Jul-18E
`1.4%
`-14.0%
`-37.8%
`3.3%
`
`-5.9%
`-4.6%
`5.8%
`-30.6%
`-36.4%
`-16.4%
`
`NM
`NM
`1.8%
`0.2%
`
`Aug-18E
`0.6%
`-13.4%
`-36.4%
`2.1%
`
`Sep-18E
`-0.5%
`-12.0%
`-33.9%
`1.8%
`
`Oct-18E
`-0.9%
`-11.5%
`-35.1%
`0.9%
`
`Nov-18E
`-1.1%
`-10.1%
`-31.3%
`0.1%
`
`Dec-18E
`-1.0%
`-9.0%
`-29.7%
`0.5%
`
`-6.8%
`-5.9%
`3.4%
`-25.9%
`-36.3%
`-15.0%
`
`NM
`NM
`1.3%
`-0.6%
`
`-6.1%
`-6.8%
`2.2%
`-25.0%
`-31.7%
`-14.4%
`
`NM
`NM
`1.6%
`-1.2%
`
`-5.7%
`-8.1%
`1.9%
`-21.0%
`-26.9%
`-13.6%
`
`NM
`NM
`2.0%
`-1.6%
`
`-5.3%
`-9.3%
`0.8%
`-23.6%
`-26.1%
`-12.1%
`
`NM
`NM
`1.3%
`-1.9%
`
`-5.2%
`-9.9%
`0.1%
`-19.3%
`-22.6%
`-11.7%
`
`NM
`NM
`2.9%
`-1.7%
`
`2018E
`1.5%
`-16.8%
`-40.9%
`3.5%
`
`-7.9%
`-5.2%
`4.5%
`-33.5%
`-40.7%
`-19.4%
`
`NM
`NM
`-0.8%
`-0.2%
`
`2019E
`0.1%
`-7.0%
`0.0%
`1.4%
`
`0.3%
`-3.8%
`1.6%
`74.6%
`-1.7%
`-17.8%
`
`189.9%
`264.4%
`6.8%
`0.4%
`
`
`
`Source: Company reports, IMS database and UBS estimates
`
`
`
`
`
` U.S. Pharmaceuticals 6 April 2018
`
`
`
` 52
`
`Mylan Ex.1089
`Mylan v. Sanofi - IPR2018-01676
`
`

`

`Feb-17
`157
`4.9%
`50.2%
`
`Feb-17
`36.3%
`3.5%
`9.8%
`
`0.2%
`0.7%
`7.1%
`6.3%
`0.5%
`
`Mar-17
`147
`-10.5%
`48.9%
`
`Mar-17
`28.5%
`4.2%
`11.5%
`
`0.8%
`0.5%
`10.6%
`9.9%
`1.0%
`
`Apr-17
`153
`21.1%
`49.7%
`
`Apr-17
`19.2%
`3.2%
`6.1%
`
`4.2%
`0.3%
`6.1%
`12.7%
`0.6%
`
`May-17
`140
`-6.4%
`50.5%
`
`May-17
`30.3%
`4.5%
`9.2%
`
`1.0%
`0.3%
`11.0%
`10.8%
`0.6%
`
`Jun-17
`133
`-11.3%
`41.7%
`
`Jun-17
`34.8%
`5.0%
`7.9%
`
`0.7%
`0.5%
`8.4%
`9.1%
`0.1%
`
`Jul-17
`133
`-17.5%
`50.1%
`
`Jul-17
`37.4%
`2.8%
`7.0%
`
`1.0%
`0.6%
`8.0%
`10.5%
`0.8%
`
`Aug-17
`135
`5.7%
`49.1%
`
`Aug-17
`24.5%
`5.5%
`8.6%
`
`0.8%
`0.3%
`9.5%
`7.0%
`0.8%
`
`Sep-17
`139
`4.7%
`48.3%
`
`Sep-17
`31.7%
`4.3%
`11.1%